CONSULTING AGREEMENTConsulting Agreement • December 5th, 2022 • Oncocyte Corp • In vitro & in vivo diagnostic substances • Tennessee
THIS CONSULTING AGREEMENT (this “Agreement”), dated as of December 1, 2022 is hereby entered into by and between OncoCyte Corporation (the “Company”) and Ronald A. Andrews (the “Consultant” and, collectively with the Company, the “Parties”).
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMSConfidential Separation Agreement and General • December 5th, 2022 • Oncocyte Corp • In vitro & in vivo diagnostic substances
This Confidential Separation Agreement and General Release of All Claims, dated December 1, 2022 (the “Agreement”), is made pursuant to that certain Change in Control Severance Agreement effective as of March 1, 2020 (the “Severance Agreement”) entered into by and between Ronald Andrews (“Employee”) on the one hand, and Oncocyte Corporation (the “Company”), on the other. This Agreement is entered into in consideration for and as condition precedent to the Company providing separation benefits to Employee pursuant to the Severance Agreement. It is understood and agreed that the Company is not otherwise obligated to provide such benefits under the terms of the Severance Agreement and that the Company is doing so as a direct result of Employee’s willingness to agree to the terms hereof. Collectively, Employee and the Company shall be referred to as the “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • December 5th, 2022 • Oncocyte Corp • In vitro & in vivo diagnostic substances • California
EMPLOYMENT AGREEMENT (“Agreement”) is entered into effective as of December 2, 2022 (the “Effective Date”), by and between OncoCyte, Corporation (the “Company”), a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs (“Executive”).
Amended and restated CHANGE IN CONTROL AND EXECUTIVE SEVERANCE PLAN AGREEMENTSeverance Plan Agreement • December 5th, 2022 • Oncocyte Corp • In vitro & in vivo diagnostic substances • Delaware
This Amended and Restated Change in Control and Executive Severance Plan Agreement (the “Agreement”) is entered into by and between Josh Riggs (“you” or “your”) and Oncocyte Corporation (the “Company”). This Agreement has an effective date of December 2, 2022 (the “Effective Date”). The Board has authorized the Company to enter into this Agreement in order for you to become a Covered Employee participant under the Oncocyte Corporation Change in Control and Severance Plan (the “Plan”). This Agreement enumerates the Plan benefits that may be provided to you as a Covered Employee as referenced in Section II of the Plan. All provisions of this Agreement are subject to and governed by the terms of the Plan. In the event of any conflict in terms between the Plan and this Agreement, the terms of the Plan shall prevail and govern.
